CG
LSTA icon

Caprock Group’s Lisata Therapeutics LSTA Stock Holding History

Caprock Group’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-136
Closed -$12K – 378
2016
Q2 		$12K Buy
+136
New +$12.5K ﹤0.01% 277
2016
Q1 		– Sell
-136
Closed -$22K – 346
2015
Q4 		$22K Buy
+136
New +$25K 0.01% 87
2015
Q2 		– Sell
-113
Closed -$43K – 84
2015
Q1 		$43K Hold
113
– – 0.04% 79
2014
Q4 		$64K Buy
+113
New +$76.9K 0.07% 94

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EGA
Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Caprock Group's LSTA Position: Q3 2016 in Review

Caprock Group sold out of Lisata Therapeutics (LSTA) in Q3 2016, closing a stake of 136 shares — an estimated $12K sold.

Caprock Group first reported a position in LSTA in Q4 2014 and held it in 4 quarters. The position peaked at $64K in Q4 2014. 28 funds tracked by Wall St. Rank hold LSTA as of Q3 2016.

  • Caprock Group reported no remaining Lisata Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Caprock Group sold 136 Lisata Therapeutics shares in Q3 2016, an estimated $12K.
  • Caprock Group first reported a position in Lisata Therapeutics in Q4 2014 and held it in 4 quarters.
  • Caprock Group's Lisata Therapeutics position peaked at $64K in Q4 2014.
  • 28 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2016.

Based on Caprock Group's 13F filing for Q3 2016, filed 15 Nov 2016.